The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Open accessAbstract
Objective To determine the availability of data on overall survival and quality of life benefits of cancer drugs approved in Europe. Design Retrospective cohort study. Setting Publicly accessible regulatory and scientific reports on cancer approvals by the European Medicines Agency (EMA) from 2009 to 2013. Main outcome measures Pivotal and postmarketing trials of cancer drugs according to their design features (randomisation, crossover, blinding), comparators, and endpoints. Availability and magnitude of benefit on overall survival or quality of life determined at time of approval and after market entry. Validated European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) used to assess the clinical value of the reported gains in published studies of cancer drugs. Results From 2009 to 2013, the EMA approved the use of 48 cancer drugs for 68 indications. Of these, eight indications (12%) were approved on the basis of a single arm study. At the time of market approval, there was significant prolongation of survival in 24 of the 68 (35%). The magnitude of the benefit on overall survival ranged from 1.0 to 5.8 months (median 2.7 months). At the time of market approval, there was an improvement in quality of life in seven of 68 indications (10%). Out of 44 indications for which there was no evidence of a survival gain at the time of market authorisation, in the subsequent postmarketing period there was evidence for extension of life in three (7%) and reported benefit on quality of life in five (11%). Of the 68 cancer indications with EMA approval, and with a median of 5.4 years’ follow-up (minimum 3.3 years, maximum 8.1 years), only 35 (51%) had shown a significant improvement in survival or quality of life, while 33 (49%) remained uncertain. Of 23 indications associated with a survival benefit that could be scored with the ESMO-MCBS tool, the benefit was judged to be clinically meaningful in less than half (11/23, 48%). Conclusions This systematic evaluation of oncology approvals by the EMA in 2009-13 shows that most drugs entered the market without evidence of benefit on survival or quality of life. At a minimum of 3.3 years after market entry, there was still no conclusive evidence that these drugs either extended or improved life for most cancer indications. When there were survival gains over existing treatment options or placebo, they were often marginal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A. A. D. S., Mayer, J., Offner, F., Rule, S. A., Teixeira, A., Walewski, J. A., Vos, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045 · Cited by 1,631
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5730 · Cited by 978
McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
ESMO Symposium on Immuno-Oncology 2015 Officers and Organisation
(2015) · Annals of Oncology · doi:10.1093/annonc/ · Cited by 733
Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., Scheithauer, W., Siena, S., Tabernero, J., Teixeira, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju413 · Cited by 658
Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547
Peppercorn, J. M., Smith, T. J., Helft, P. R., DeBono, D. J., Berry, S. R., Wollins, D. S., Hayes, D. M., Von Roenn, J. H., & Schnipper, L. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1744 · Cited by 524
Gianni, L., Eiermann, W., Semiglazov, V., Lluch, A., Tjulandin, S., Zambetti, M., Moliterni, A., Vazquez, F., Byakhov, M. J., Lichinitser, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70080-4 · Cited by 490
Prasad, V., Kim, C., Burotto, M., & Vandross, A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.2829 · Cited by 403
Kim, C., & Prasad, V. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.5868 · Cited by 354
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp177 · Cited by 349
Progression-Free Survival: Meaningful or Simply Measurable?
Booth, C. M., & Eisenhauer, E. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7571 · Cited by 324
Fojo, T., Mailankody, S., & Lo, A. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 303
Endpoints for Assessing Drug Activity in Clinical Trials
Pazdur, R. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s2-19 · Cited by 286
Cancer Drugs in the United States: Justum Pretium—The Just Price
Kantarjian, H. M., Fojo, T., Mathisen, M., & Zwelling, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1845 · Cited by 284
Blumenthal, G. M., Karuri, S. W., Zhang, H., Zhang, L., Khozin, S., Kazandjian, D., Tang, S., Sridhara, R., Keegan, P., & Pazdur, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0489 · Cited by 218
Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
(2007) · Biotechnology Law Report · doi:10.1089/blr.2007.9941 · Cited by 196
Naci, H., Smalley, K. R., & Kesselheim, A. S. (2017) · JAMA · doi:10.1001/jama.2017.9415 · Cited by 195
Self-citationHatswell, A. J., Baio, G., Berlin, J. A., Irs, A., & Freemantle, N. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011666 · Cited by 186
Doyle, C., Crump, M., Pintilie, M., & Oza, A. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1266 · Cited by 183
Saad, E. D., Katz, A., & Buyse, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5414 · Cited by 178
Evolution of the Randomized Controlled Trial in Oncology Over Three Decades
Booth, C. M., Cescon, D. W., Wang, L., Tannock, I. F., & Krzyzanowska, M. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5456 · Cited by 162
Aggarwal, A., Fojo, T., Chamberlain, C., Davis, C., & Sullivan, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx110 · Cited by 162
Self-citationWoods, A. P., Krumholz, H. M., Downing, N. S., Aminawung, J. A., Shah, N. D., & Ross, J. S. (2017) · BMJ · doi:10.1136/bmj.j1680 · Cited by 124
Relevance of randomised controlled trials in oncology
Tannock, I. F., Amir, E., Booth, C. M., Niraula, S., Ocaña, A., Šeruga, B., Templeton, A. J., & Vera-Badillo, F. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30572-1 · Cited by 122
Chen, G., Feng, J., Zhou, C., Wu, Y.-L., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt012 · Cited by 121
Amir, E., Šeruga, B., Kwong, R., Tannock, I. F., & Ocaña, A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.028 · Cited by 119
When are ‘positive’ clinical trials in oncology truly positive?
Ocana, A., & Tannock, I. F. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq463 · Cited by 110
Apolone, G., Joppi, R., Bertelè, V., & Garattini, S. K. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602750 · Cited by 107
Why do our patients get chemotherapy until the end of life?
Braga, S. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr416 · Cited by 104
Outcomes and endpoints in cancer trials: bridging the divide
Wilson, M. K., Collyar, D. E., Chingos, D. T., Friedlander, M. L., Ho, T. W., Karakasis, K., Kaye, S. B., Parmar, M., Sydes, M. R., Tannock, I. F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70380-8 · Cited by 100
Early market access of cancer drugs in the EU
Martinalbo, J., Bowen, D., Camarero, J., Chapelin, M., Démolis, P., Foggi, P., Jönsson, B., Llinares, J., Moreau, A., O’Connor, D. J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv506 · Cited by 96
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
Paggio, J. C. D., Biju Azariah, M., Sullivan, R. J., Hopman, W. M., James, F. V., Roshni, S., Tannock, I. F., & Booth, C. M. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw538 · Cited by 90
Drugs, cancer and end-of-life care: A case study of pharmaceuticalization?
Davis, C. (2014) · Social Science & Medicine · doi:10.1016/j.socscimed.2014.12.007 · Cited by 89
Self-citationCiani, O., Davis, S., Tappenden, P., Garside, R., Stein, K., Cantrell, A. J., Saad, E. D., Buyse, M. E., & Taylor, R. S. (2014) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462314000300 · Cited by 87
Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints
Rupp, T., & Zuckerman, D. M. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.7761 · Cited by 73
Guérin, A., Chen, L., Ionescu‐Ittu, R., Marynchenko, M. B., Nitulescu, R., Hiscock, R., Keir, C. H., & Wu, E. Q. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.944973 · Cited by 72
Rare Cancer Trial Design: Lessons from FDA Approvals
Gaddipati, H., Liu, K., Pariser, A., & Pazdur, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1135 · Cited by 63
Wilkerson, J., & Fojo, T. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bef8cd · Cited by 62
Use of the conditional marketing authorization pathway for oncology medicines in Europe
Hoekman, J., Boon, W., Bouvy, J. C., Ebbers, H. C., de Jong, J., & Bruin, M. L. D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.174 · Cited by 60
Naci, H., Wouters, O. J., Gupta, R., & Ioannidis, J. P. A. (2017) · Milbank Quarterly · doi:10.1111/1468-0009.12261 · Cited by 59
Self-citationProgress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception
Saltz, L. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6198 · Cited by 50
Cancer drugs, survival, and ethics
Wise, P. H. (2016) · BMJ · doi:10.1136/bmj.i5792 · Cited by 49
Why do cancer drugs get such an easy ride?
Light, D. W., & Lexchin, J. (2015) · BMJ · doi:10.1136/bmj.h2068 · Cited by 42
Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life?
(2013) · PsycEXTRA Dataset · doi:10.1037/e553812013-001 · Cited by 36
Approvals in 2016: questioning the clinical benefit of anticancer therapies
Booth, C. M., & Paggio, J. C. D. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.18 · Cited by 34
Österborg, A., Udvardy, M., Zaritskey, A. Y., Andersson, P., Grosicki, S., Mazur, G. J., Kaplan, P., Steurer, M., Schuh, A., Montillo, M., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1122783 · Cited by 27
Raising the bar for market authorisation of new drugs
Naci, H., Cylus, J., Vandoros, S., Sato, A., & Perampaladas, K. (2012) · BMJ · doi:10.1136/bmj.e4261 · Cited by 26
Self-citationSalas-Vega, S., & Mossialos, E. A. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1453 · Cited by 25
Reality Check for Pemetrexed and Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
Murray, N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3448 · Cited by 12
Cited by
Mortality due to cancer treatment delay: systematic review and meta-analysis
Hanna, T. P., King, W. D., Thibodeau, S., Jalink, M., Paulin, G. A., Harvey-Jones, E., O’Sullivan, D. E., Booth, C. M., Sullivan, R., & Aggarwal, A. (2020) · BMJ · doi:10.1136/bmj.m4087 · Cited by 1,742
Self-citationPerioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
Gyawali, B., Hey, S. P., & Kesselheim, A. S. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0462 · Cited by 300
Costa, S., Bentley, C., Regier, D. A., McTaggart-Cowan, H., Mitton, C., Burgess, M. M., & Peacock, S. J. (2019) · BMC Public Health · doi:10.1186/s12889-019-7303-2 · Cited by 22
Metadata
- Authors
- Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., & Aggarwal, A.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2017-10-04
- Volume
- 359
- Pages
- j4530
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2761792472
- Cited by
- 599
- References
- 78
- FWCI
- 139.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.